- Expects top-line data from LEAP 1 CABP Phase 3 trial in third quarter 2017 and from LEAP 2 CABP Phase 3 trial in first quarter 2018 Vienna, Austria / King of Prussia, PA, May 12, 2017 – Nabriva Therapeutics AG (NASDAQ: NBRV), a clinical stage biopharmaceutical company engaged in the research and
VIENNA, Austria and KING OF PRUSSIA, Pa. , April 19, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin
VIENNA, Austria , April 17, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV) (" Nabriva AG ") announced that its supervisory board and management board approved the relocation of the holding company of Nabriva AG and its subsidiaries (" Nabriva Group ") from Austria to Ireland (the "
Nine abstracts support potential for lefamulin as a first-line, empiric treatment for patients with community-acquired bacterial pneumonia VIENNA, Austria and KING OF PRUSSIA, Pa. , April 13, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company
VIENNA, Austria and KING OF PRUSSIA, Pa. , April 11, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin
VIENNA, Austria and KING OF PRUSSIA, Pa. , March 27, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin
VIENNA, Austria and KING OF PRUSSIA, Pa. , March 24, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin
VIENNA, Austria and KING OF PRUSSIA, Pa. , Feb. 27, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
VIENNA, Austria , and KING OF PRUSSIA, Pa. , Feb. 08, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin
LEAP 1 top-line efficacy and safety data expected in 3Q17 VIENNA, Austria , and KING OF PRUSSIA, Pa. , Feb. 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat
